Dr Barbara Morera Presents at French Network for Tourette Syndrome Conference as Guest Speaker

 Dr Barbara Morera, Chief Research Officer at Neupulse, recently delivered an inspiring presentation at the 17^th annual meeting of the French Network for Tourette Syndrome. Dr Morera highlighted Neupulse's journey from groundbreaking research at the University of Nottingham to its current work advancing a non-invasive, wearable device aimed at reducing tics in individuals with Tourette Syndrome and Chronic Tic Disorder.

Her talk emphasized Neupulse’s commitment to making the device widely accessible. The audience showed strong interest in the potential of Neupulse’s wearable device, underscoring the impact this innovation could have on improving lives and expanding treatment options for individuals with tic disorders.

About the company 

Since incorporation in February 2021 Neupulse has achieved several significant milestones including development of a prototype device for use in a double-blind study. This double-blind, sham-controlled trial completed recruitment of more than 130 individuals with Tourette Syndrome in 2022 testing new and exciting wrist stimulation research designed by some of the world’s leading neuroscientists. The company has completed analysing the data from the trial with the results published in Q2 2023. The company is currently working on the development of the commercially available device.

About Tourette Syndrome 

Tourette Syndrome is an often-debilitating condition that effects millions of individuals around the world. Tourette Syndrome almost always starts in early childhood meaning individuals with the condition are typically young children. Tourette Syndrome causes sufferers to make involuntary sounds and movements called tics that can be painful, embarrassing and difficult if not impossible to control. The majority of individuals with the condition also have other taxing co-occurring conditions such as attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD) and anxiety. Many individuals with Tourette Syndrome have high intelligence, quick wit and are artistic and have other exceptional abilities yet the condition is still stigmatised and they are poorly understood by the public and even by medical professionals often leading to challenging social lives for those with the condition. While many with Tourette Syndrome find that their tics and other symptoms improve as they move into adulthood this is not always the case and the negative effects of dealing with the condition during school years can be significant for both individuals and their families. There is no cure for Tourette Syndrome and current medications and treatment options are of limited and questionable availability and efficacy. Neupulse is excited to continue to work towards becoming the first truly effective, non-invasive treatment option for those with the condition which is believed to affect more than 1.5% of the world’s population or 120 million people and more than 2% of the world’s children or 40 million children. 

Media contact: enquiries@neupulse.co.uk